What Is New in Glaucoma: From Treatment to Biological Perspectives by Nuzzi, R. et al.
Review Article
What Is New in Glaucoma: From Treatment to
Biological Perspectives
Raffaele Nuzzi ,1 Paola Marolo ,1 and Alessia Nuzzi 2
1Eye Clinic Section, Department of Surgical Sciences, University of Turin, Turin, Italy
2Department of Clinical Sciences and Community Health, Eye Clinic San Giuseppe Hospital,IRCCS Multimedica,
University of Milan, Milan, Italy
Correspondence should be addressed to Raffaele Nuzzi; prof.nuzzi_raffaele@hotmail.it
Received 3 January 2020; Revised 24 February 2021; Accepted 24 March 2021; Published 14 April 2021
Academic Editor: Steffen Heegaard
Copyright © 2021 Raffaele Nuzzi et al.,is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Glaucoma is a chronic silent disease and an irreversible cause of blindness worldwide. Research has made many efforts to improve
disease control and especially to anticipate both early diagnosis and treatment of advanced stages of glaucoma. In terms of
prevention, networking between professionals and nonprofessionals is an important goal to disseminate information and help
diagnose the disease early. On the other hand, the most recent approaches to treat glaucoma outcomes in its advanced stages
include electrical stimulation, stem cells, exosomes, extracellular vesicles, and growth factors. Finally, neuronal plasticity-based
rehabilitation methods are being studied to reeducate patients in order to stimulate their residual visual capacity. ,is review
provides an overview of new approaches to future possible glaucoma treatment modalities and gives insight into the perspectives
available nowadays in this field.
1. Introduction
Glaucoma is one of the leading causes of blindness in the
world, second only to cataracts [1, 2]. It is a chronic, de-
generative disease affecting the optic nerve, but insidious: in
fact, when the etiopathogenetic process has started and has
already damaged the nerve fibers, the symptomatology is
almost silent [3, 4]. When the patient becomes aware of the
visual impairment, the neural function is already compro-
mised and the chances of recovery are significantly reduced.
,ere is no scientific evidence of the field of visual recovery
once its defect has been documented. However, a perimetric
learning effect among a percentage of patients could occur,
very unlikely to represent a real improvement. For these
reasons, glaucoma is a disease of enormous social impact,
both from the human point of view, because it is highly
disabling and compromises the quality of life and autonomy
of those affected [5], and from an economic point of view: for
its clinical-therapeutic management, in fact, a substantial
percentage of public healthcare expenditure is invested [6].
,e term “glaucoma” actually encompasses several forms of
optical neuropathies with still partly obscure etiopatho-
genesis associated with typical visual field alterations and
increased intraocular pressure [7, 8]. In reality, this last
characteristic is not the rule: in recent years, the number of
cases of “normotensive glaucoma,” which is not associated
with an increment in IOP, has increased dramatically, es-
pecially in relation to the lengthening of life expectancy
[9, 10]. In fact, it has long been known that only about half of
the glaucoma cases have intraocular pressure above refer-
ence values [11–13]. In any case, the most accredited etio-
pathogenetic hypothesis would be the death of retinal
ganglion cells due to mechanical stress and apoptosis fol-
lowing ischemic and/or chemical mechanisms, which would
seem to have glutamate and NMDA receptor activation as
protagonists, which would cause an exponential increase in
intracellular calcium concentration, thus triggering irre-
versible damage to DNA and cell death [14, 15]. In light of
this, it is clear that it is of great importance to study the
phases of this disorder and to continually seek new pre-
ventive and therapeutic strategies [16]. According to the
current scientific panorama, the therapeutic possibilities are
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aimed at acting both on the initial stages of the disease and
on the final outcomes, i.e., on the advanced stages of
glaucoma for which the lesions are considerable and no
longer reversible, but in which it is possible to intervene by
enhancing the residual functions at the highest level. In this
context, the aim of our manuscript is to provide a com-
prehensive review of the recently investigated new ap-
proaches to treat early and late stages of the disease.
,is literature search was performed in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [17]. Studies reporting
novel treatment strategies of glaucoma were systematically
reviewed. PubMed, MEDLINE, Web of Science, and Embase
databases (from inception up to 1 January, 2020) were
searched. ,e electronic search method included the terms
‘glaucoma’, ‘novel therapies’, ‘electrical stimulation’,
‘micropulse’, ‘stem cells’, ‘exosomes’, ‘optic nerve regener-
ation’, ‘growth factors’, ‘rehabilitation’, which were con-
nected in various combinations by ‘or’/’and’. ,e last search
was carried out on 1 January, 2020. Either prospective or
retrospective, both randomized and not randomized studies
were considered for eligibility. No restrictions in terms of
follow-up were applied. Eligible papers must have been
published in peer-reviewed journals and in English, with no
publication date or publication status limitations. Titles and
abstracts of all identified studies were independently
reviewed by two researchers (P.M. and A.N.) to assess eli-
gibility. A full-text evaluation of all potential studies was
performed later. Once studies have been selected and in-
cluded, data were extracted by two independent investiga-
tors (P.M. and A.N.). When discrepancies were found, a
third author (R.N.) was involved to achieve consensus.
2. Overview of the Current Evolution of
Treatment Strategies
In addition to the well-known hypotensive drugs, in recent
years, research has focused on the development of new local
and systemic drugs to be used to reduce intraocular pressure.
,e main innovative drugs discovered are latrunculin de-
rivatives, ROCK inhibitors, cannabinoids, local calcium
channel blockers, and A1 receptor agents. Latrunculin de-
rivatives have mild hypotonic properties and low solubility
[18], while ROCK inhibitors have been shown to be effective
in reducing pressure in animal models, also acting as
neuroprotectors and vasoregulators [19, 20]. ,ese agents
seem to interfere with the healing that generally occurs after
filtering surgery [21]. Cannabinoids increase the outflow of
aqueous humor that acts on ciliary processes with a vaso-
dilator effect and increase PGE2 levels [22–24]. A1 receptor
agonists [25] and selective calcium channel blockers im-
prove watery mood drainage, but the latter can lead to
serious systemic consequences, such as severe bradycardia
and arterial hypotension [26].
Moreover, in the last years, great interest has been de-
voted to the design of modern devices for instilling drugs in
situ: one of the main disadvantages of eye drops treatment is,
in fact, the poor compliance and fluctuating adherence of
patients to the therapy [27]. ,ese new delivery systems
include eye inserts, surgical implants, soft medicated contact
lens, and nanospheres. Ocular inserts are projected to
provide medication for several days, while surgical implants
can perform their function for months but require surgical
intervention [28]. Another product in the design phase is the
medicated soft contact lens, which, however, must be worn
constantly and does not always allow drugs to pass through
the surface of the eye in adequate quantities [27, 29].
Nanospheres are another type of device that ensures good
drug penetration but does not prevent the patient’s from
poor adherence to therapy because these microspheres are
administered through eye drops [30]. To date, the experi-
mental data in favor of the application of these delivery
systems are promising but still limited, and further studies
are needed to confirm such evidence [31].
Concerning laser therapy, diode laser trabeculoplasty
(DLT) uses lower energy spots than SLT (selective laser
trabeculoplasty) and ALT (argon laser trabeculoplasty) for
the same performance, and micropulse diode laser trabe-
culoplasty (MDLT) emits microspots to limit heat-induced
damage to adjacent structures [32]. Ab intero excimer laser
trabeculectomy is based on the creation of microperforation
connecting the anterior chamber to the Schlemm’s channel,
theoretically not causing heat-induced damage and healing
[33].
However, its effectiveness is still uncertain. Despite the
advantages of laser technology, research is still focusing on
finding the best way to minimize tissue rupture and sub-
sequent healing and to achieve better effectiveness in terms
of lowering IOP.
Regarding surgery, the main goal of the latest research
has been to improve its risk/benefit ratio, trying to overcome
the traditional trabeculectomy technique, which still re-
mains the gold standard of treatment. Minimally invasive
glaucoma surgery (MIGS) [34] has been developed in an
attempt to obtain a better efficacy/safety ratio in eyes with
mild or medium-mild grade glaucoma.,e efficacy of MIGS
is lower in IOP reduction compared to standard surgery, and
its costs are elevated; nevertheless, it is a safe technique and
can play a role in a subgroup of patients who are not willing
to undergo regular surgery or when patients with a moderate
level of pressure lowering do not tolerate drops or do not
respond to laser treatment.
3. Novel Treatment Strategies for
Glaucoma Outcomes
Despite the numerous therapeutic efforts described above,
glaucoma is often diagnosed late and blocking the natural
evolution of the disease is still the main obstacle in its
management. Delaying therapies to the more advanced
stages of glaucoma leads to its evolution towards irreversible
optic nerve damage and blindness. In this respect, numerous
studies have examined the action of new molecules and
techniques to improve the control of the disease and restore
lost nerve function and protect its anatomical and functional
residuals. It is possible to intervene both separately and
concurrently on four levels: the trabecular meshwork, the
ciliary body, the retinal ganglion cells (RGCs), and the optic
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nerve. ,e main approaches concern the use of stem cells,
exosomes or extracellular vesicles, neuroprotection, and
rehabilitation therapy. As far as the optic nerve is concerned,
the most encouraging instruments are growth factors and
chitosan sheaths.
In this section, we will focus our attention on the latest
discoveries on the treatment of glaucoma, explaining for
each strategy which aspects of the disease it targeted, its
underlying mechanisms and/or molecules, its development
phase, and the main obstacles to be overcome in order to
bring it to the clinic.
3.1. Electrical Stimulation of the Trabecular Meshwork.
Electrical stimulation has recently been proposed as a novel
approach to decrease IOP in open-angle glaucoma [35]. ,e
target of this technique is the trabecular meshwork (TM),
which is not just a passive way of drainage of the aqueous
humor but also has an active role in the resistance to the
passage of AH through mechanisms that are not fully un-
derstood [36]. Early transcorneal electrical stimulation
(TcES) [37] has been shown to have a positive IOP lowering
effect in preclinical studies. RGCs in the eyes of gerbil prone
to retinal lesions related to acute ocular hypertension have
been protected from damage by TcES. ,e implicit mech-
anism of action was the modulation of the inflammatory
response activated by microglial cells [37]. Transpalpebral
electrical stimulation (TES) performed on human eyes with
open-angle glaucoma has been shown to have a significant
effect in lowering IOP [35]. ,e purpose of TES is to re-
produce the role of tyrosine kinase inhibitors by stimulating
the reactivation of calcium-activated potassium channels in
TM cells. ,e hyperpolarization induced by the efflux of
potassium to TM promotes its relaxation and thus facilitates
the outflow of aqueous humor to Schlemm’s channel. ,e
progressive functional damage of the TM in glaucoma is
inversely proportional to the effectiveness of electrical
stimulation. When the ion channel dysfunction is too ad-
vanced and both the volume and the elasticity of TM cells are
affected, it is more difficult to obtain a good response. Less
trabecular function in more advanced glaucoma results in
reduced efficacy of the procedure and increased need to
replicate it. ,erefore, it is our opinion that electrical
stimulation may be more useful in the early stages of the
disease. Additional studies are needed to further investigate
this new technique and to evaluate the maintenance of the
IOP lowering effect in time after treatment.
3.2. Micropulse Cyclophotocoagulation and Ultrasound
Cyclomodification. Cilioablation is a well-known procedure
that has undergone a drastic evolution in basic technology in
recent years. While prostaglandin analogues activate the
receptors of the smooth muscles of the ciliary body and
increase the uveoscleral outflow, surgical ablation of a ciliary
body part can decrease the secretory activity of the ciliary
epithelium, thus reducing IOP. Diode laser cyclo-
photocoagulation (CPC) has shown an encouraging risk-
benefit profile, with a much more tolerable side effect profile
than previous cyclocryotherapy and has led to the
development of transscleral diode CPC and endoscopic
diode CPC.
Advances in the study of diode technology have allowed
the development of the new transscleral Micropulse Diode
laser CPC. Its diode laser emits a series of short (micro-
second), repetitive bursts of energy, so that the thermal effect
is limited to the absorbing tissue with minimal heat diffusion
to adjacent structures. During the cooling period, the tissue
has time to relax and return to the base temperature.
Micropulse diode laser technology has been successfully
used for the treatment of diabetic retinopathy and macul-
opathy, and the expectation on glaucoma is to achieve the
same IOP lowering effect as traditional CPC diode, with
fewer associated side effects. Tan et al. [38] conducted a study
in which good rates of IOP andmed reduction were detected
and about one-third of the patients reported suffering pain
during the procedure, while none described the discomfort
as moderate or severe. Although the initial results are en-
couraging, further studies with longer follow-up are re-
quired to better assess the actual benefits of CPC micropulse
compared to traditional CPC. Efforts in the search for an
alternative to cyclodestructive procedures to further reduce
tissue damage have led to the introduction of high-intensity
ultrasound (HIFU) for the treatment of glaucoma. ,e
device, firstly proposed in 1991 [39], has recently been
redesigned into a compact and easy-to-use device (EyeOP1,
EyeTechCare, Rillieux-la-Pape, France). ,e two essential
components of the system are the generator, which gives
power to piezoelectric transducers, and the pressure re-
duction system, which modulates the suction of the probe
with its ultrasonic beam. ,e device uses what is known as
circular ultrasound cyclocoagulation and simultaneously
treats the entire ciliary body through the release of a ti-
tratable dose of six distinct ultrasonic energy beams. In the
first clinical study on this procedure [40], a good response to
IOP lowering was obtained in the treated group with a
duration of four seconds of ultrasound exposure per shot
and the complications were three cases of superficial
punctate epitheliopathy and one of central ulcer, with no
reports of chronic pain hypotony or phthisis bulbs.
Considering that cyclodestructive procedures have been
used to treat the later stages of glaucoma, particularly
neovascular glaucoma, it is not surprising that the results are
mostly poor in the literature. Recently, some studies have
evaluated the use of the new technologies described to treat
earlier stages of glaucoma, and this has been possible thanks
to their good safety profile [41, 42]. With the increase in
supporting evidence, more and more surgeons are now
considering these new technologies in the treatment of early
stages of glaucoma rather than more advanced cases.
3.3. StemCells)erapy. Stem cells are an important resource
for the maintenance, repair, and possible regeneration of
anatomical structures such as the optic nerve [43]. ,e
scientific interest in these cells is due to their unique
properties, including the capacity to divide themselves an
infinite number of times and the ability to differentiate into
many types of cells. However, ethical concerns and technical
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barriers are still implied. Promising results have been re-
ported in the literature, but further research is required in
order to bring its application to the clinic. To date, the most
used cell lines are adult limbic stem cells to restore the
corneal epithelium [44], those situated at the location of
Schwalbe’s ring (the transitional zone between the corneal
endothelium and the TM) [45, 46] and those of the ciliary
epithelium, which seem to be able to differentiate into
various retinal cell strains [47–49]. With regard to differ-
entiation into neural and retinal cells, embryonic/progeni-
tors retinal stem cells have demonstrated successful
differentiation into retinal cell types, either in vitro [50] or in
vivo [51]. Nevertheless, their use for ex vivo cell therapy still
presents barriers: insufficient availability of stem cells/pro-
genitors, immune rejection, and clinical issues related to
embryonic and fetal origins. To overcome this hurdle,
Parameswaran et al. [48] have demonstrated that mouse
fibroblast induced pluripotent stem cells (iPSCs) were also
able to generate RGCs, rods, cones, and photoreceptors. ,e
iPSCs were stimulated by a simulated microenvironment of
late retinal histogenesis and finally expressed retinal cell
type-specific regulators. Anyway, the clinical application of
iPSCs for cell therapy in glaucoma is still unknown, and in
order to consider the use of stem cells as a replacement for
RGCs, some challenges should be addressed. First, the
stimulation method of transplanted stem cells is not yet fully
understood and further studies are needed in order to bring
functional results to the damaged optic nerve in glaucom-
atous eyes. In addition, RGCs have a heterogeneous nature
with different morphological and molecular criteria, making
the induced differentiation progress even more challenging.
Other types of stem cells that can be employed are mes-
enchymal stem cells (MSCs) from bone marrow and adipose
tissue [52]. ,e main advantages of MSCs are their plu-
ripotency, their ease of extraction, and their availability for
autologous transplantation. ,e neuroprotective effects of
MCSs in experimental glaucoma are now gaining more and
more evidence in experimental glaucoma models [52, 53].
MSCs have also shown the ability to produce neurotrophic
factors, such as brain-derived neurotrophic factor (BDNF)
and ciliary neurotrophic factor (CNTF), with a 28% re-
duction of cell death after 1 month from glaucoma onset
[54]. Connick et al. [55] have suggested a promising ap-
plication of MSCs that demonstrates positive effects in
patients with multiple sclerosis after their intravenous ad-
ministration. Visual acuity and visual evoked potential la-
tency have improved. It would be interesting to evaluate the
possibility of reintegrating trabecular cells by transplanting
MSCs into the anterior chamber. ,e hydrodynamics of
aqueous humor should allow the cells to settle at the iri-
docorneal level, with phenomena of differentiation and
intratissue migration. However, experimental data sup-
porting their application in glaucoma are few, except for the
production of neurotrophic factors by transplanted stem
cells that stimulate ganglion cells survival.
3.4. Exosomes or Extracellular Vesicles. Recent studies have
demonstrated the paracrine capacity of MSCs to secrete
exosomes [56–58]. Exosomes small extracellular vesicles of
endocytic origin of 30–100 nm diameter, with a membrane
enclosure and containing proteins, as well as mRNA and
miRNA, which can be delivered to the nearby cells. ,e
advantages of exosomes are many. First, they can be easily
isolated and purified; second, they are cell-free and do not
proliferate, thus avoiding ethical issues related to stem cells.
,ey can also be easily stored and the application of specific
doses is easier. Since they are really small, they can migrate
into the ganglion cell layer from the vitreous, and this is not
possible with transplanted cells. Furthermore, and most
importantly, exosomes are immunologically inert.
It has been proven that the content of exosomes is
translated to other cells when the exosome blends with the
nearby cell membranes and this leads to the translation of
new proteins [59]. Once the exosomes deliver their content
to cells, this is shuttled inside endocytic vesicles and de-
livered to endoplasmic reticule and lysosomes [60]. Mead
and Tomarev isolated the exosomes from stem cells derived
from bone marrow MSC (BMSC) and tested them into a
murine model [61]. ,ey performed the first study in which
RGC were treated with exosomes and, for the first time,
BMSC-derived exosomes were delivered into an eye. In their
study, a significant neuroprotective effect was shown when
the rapt optic nerve model was analyzed with optical co-
herence tomography, electroretinography, and immuno-
histochemistry. RGC survival, regeneration of axons, and
partial prevention of RGC axon loss (measured as RNFL
thickness) and preservation of RGC function (measured
with electroretinogram) were possible thanks to intravitreal
injections of BMSC-derived exosomes and were associated
with miRNA-dependent mechanisms.
However, the miRNA content and its targets have to be
better characterized, and it is not clear which dose of
intravitreal exosomes should be injected in order to have a
therapeutic effect (weekly, biweekly, or monthly). Further
research is needed to bring these promising new results into
the clinic.
3.5. Optic Nerve Axonal Regeneration. Irreversible lesions
related to the progression of glaucoma lead to optic nerve
atrophy and loss of visual functions up to blindness. It is not
necessary to emphasize how important it is to avoid such an
eventuality and how much effort and energy research have
invested for years to discover therapeutic strategies to be
adopted in this context.
One of the most investigated therapeutic approaches is
optic nerve transplantation, which can be achieved with a
peripheral nerve graft, but currently, the most promising
resource seems to be the realization of polymeric mem-
branes. ,e optic nerve transplantation is not yet ready to be
applied in human models, and further studies are needed;
anyway, many researchers are now focusing on the devel-
opment of this topic.
After any kind of optic nerve injury, the regeneration of
the optic nerve is blocked by major obstacles. ,e most
considerable ones are the following: apoptosis of RGC, the
difficulty in triggering the axonal growth, and the presence
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of inhibitory factors in the microenvironment of the central
nervous system. Concerning optic nerve regeneration, a
promising strategy is the creation of conduits that damaged
neurons and axons, which can be utilized as a guide for nerve
repair and regeneration; such conduits can be of various
kinds, and many studies are now focusing on chitosan, a
promising derivative of chitin extracted from shellfish
[62–64]. Peripheral nerve grafts demonstrated an effect on
the restoration of the pupillary reflex in mice with the
damaged optic nerve. In addition, other substrates are under
investigation. A peptide nanofiber scaffold has been studied
in hamsters, with good recovery of visual function. Negishi
et al. [65] applied a silicone tube graft enriched with purified
Schwann cells, extracellular matrix, and growth factors in
mice subjected to axotomy, showing regeneration of blood
vessels, RGC, and axons. Concerning chitosan, studies
demonstrated their utility in neural regeneration of either
the peripheral or the central nervous system [63]. In order to
facilitate neural regeneration, chitosan can be enriched with
adhesion molecules, MSCs, and neurotrophic factors. Pol-
yglycolic acid- (PGA-) chitosan scaffolds [66] and cationic
chitosan-graft-poly(ε-caprolactone)/polycaprolactone (CS-
PCL/PCL) scaffolds have been studied with promising re-
sults concerning their potential in stimulation and regen-
eration of damaged nerve fibers.
Triggering the neuronal growth implies the simultaneous
action on different intracellular signals [67]. One of the most
interesting pathways of triggering involves the ROCK in-
hibitors, which have a negative effect on the ROCK signaling
cascade (which is itself a negative regulator of neural
growth). In addition, alpha-crystallin proteins, which are
components of the ocular lens, showed antiapoptotic
properties thanks to their structural homology with heat
shock proteins with chaperone-like features [68]. Piri et al.
[69] demonstrated decreased levels of these proteins in
glaucoma models, leading to the thought that down-
regulation of these proteins may reduce RGC survival. Other
studies [68] supported this theory and further research is
ongoing in order to give some clinical application to this
interesting finding.
Molecular targets have been investigated in the field of
new glaucoma treatment strategies [70]. Death from RGC is
related to neurotrophic factor deprivation, hypoxia, exci-
totoxicity, gene dysregulation, and activation of apoptosis.
,erefore, studies have focused on the possibility of en-
hancing the BDNF-TrkB signal (brain-derived neurotrophic
factor-tyrosine protein kinase) and on the chance of
pharmacologically modulating TrKB. Endogenous phos-
phatase Shp2 was also studied, considering its role in reg-
ulating TrKB. Recent findings have shown that stress-
induced protein aggregation could cause the formation of
unfolded proteins in the ER (endoplasmic reticulum) and
apoptosis. In order to modulate the equilibrium between the
apoptotic and the survival pathways, also proapoptotic Bcl2
and antiapoptotic Bax molecules are under investigation.
Furthermore, many studies focused on the beneficial
effect of local, controlled inflammation. Vitreal inflamma-
tion induces the activation of retinal astrocytes and Müller
cells and the secretion of many glial-derived growth factors,
including BDNF, CNTF, leukemia inhibitory factor (LIF),
and bone morphogenetic proteins (BMP) [71]. ,is event
promotes neuroprotection of the RGCs and axonal growth
by interacting with macrophage-derived factors (MDF),
suggesting that immunomodulatory treatments may pro-
mote optic nerve regeneration. Intravitreal injections of
zymosan and other immunoregulatory molecules, as well as
the release of β/c-crystallins from the injured lens [72],
proved a proregenerative effect on the optic nerve. Zymosan
is a yeast cell wall carbohydrate and it is a toll-like receptor 2
(TLR-2) ligand, which stimulates the ingress of the mac-
rophages into the vitreous body and the MDF production
when injected inside the vitreous [73]. Optic nerve regen-
eration was also shown using another TLR-2 ligand, the
Pam3Cys, which is a water-soluble bisacyl-lipopeptide and a
selective TLR-2 agonist. Its intravitreal application can in-
duce glial activation, transform RGCs into a regenerative
state, and stimulate axon regeneration [74].
3.6. Neurotrophic Growth Factors. As previously mentioned,
particular attention has been dedicated to oxidative stress
and its etiopathogenetic role in glaucoma. In fact, it has been
observed that ocular hypertension establishes a stress con-
dition that stimulates oxygen-free radicals production,
which harms both directly and indirectly the retinal cells
[75]. ,e use of molecular agents capable of arresting this
oxidative burst would therefore be desirable. Currently, only
brimonidine seems to possess neuroprotective properties
and it has been shown that in patients treated with this
substance, there is a slowdown in campimetric damage
compared to those treated with timolol [76]. Another
promising molecule is citicoline, already approved in Italy,
i.e., a molecule previously involved in other neurodegen-
erative diseases, which could be used as a therapeutic tool in
addition to hypotonic pharmacological treatment. Other
interesting molecules are EPO (erythropoietin), BDNF, and
CNTF, which appear to be involved in the growth and
survival of RGCs: they are administered intravitreally,
currently, their action is transient, and their use may cause
teratogenic ocular effects. ,e most desirable resource re-
mains gene therapy, which would directly induce endoge-
nous production of these neurotrophic factors without the
need to inject them externally [70]. Gene therapy can also
take advantage of siRNA and polysaccharide or liposomal
nanoparticles that act as vectors for placing a particular gene
at a specific site [77]. ,e approach via viral vectors has
already shown promising results [78]. Recent human clinical
trials focused their attention mainly on Leber’s Hereditary
Optic Neuropathy (LHON); nevertheless, many animal
studies about other optic neuropathies and RGCs neuro-
protection have been conducted. Animal studies showed
promising results about regeneration and neuroprotection.
Concerning LHON, it has been shown that intravitreal
injections of AAV2-ND4 (adeno-associated viruses type 2
carrying NADH dehydrogenase, subunit 4 gene) viral vector
are safe and feasible [79]. However, long-term efficacy and
risks such as tumors are concerns still to be better
considered.
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Table 1: Summary of the new treatment strategies under development.
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,euse of neurotrophic factors is promising, but limited,
as there are not yet adequate techniques to selectively target
these molecules at specific sites. Moreover, they may be
beneficial for some types of cells, but toxic for others if they
reach certain concentration values; they also have a reduced
half-life. ,e solution to these challenges seems to be the
design of carrier particles that preserve the neuroprotective
molecules and direct them to the desired targets.
3.7. Rehabilitation )erapy. Rehabilitation treatment is a
therapeutic method that aims to reeducate the patient to the
use of residual vision through repeated visual stimulation.
What this technique is based on is the neuronal plasticity of
the visual system, as the damaged nerve fibers are able to
reorganize themselves and repair the injury by creating new
connections or rediscovering existing but little exploited
networks. ,erefore, if the optic nerve is completely dam-
aged (e.g., very late stages of glaucoma), it is impossible to
apply this strategy. An example of neuronal plasticity
concerning the visual system is the phenomenon of blind-
sight, which occurs in some patients suffering from cortical
blindness: Weiskrants et al. [80] described it as the capacity
of some patients to respond to visual stimuli in the corre-
sponding area of the visual field without perceiving it
consciously. ,is phenomenon may be attributed to the
recruitment of subcortical pathways in order to partially
compensate for the loss of visual functionality.
Many methods have been studied and tested to improve
vision in partially blind patients. ,ese methods include
vision training exercises such as computer-based vision
restoration therapy [2], retinal implants, and noninvasive
brain current stimulation. In the latter case, direct current or
alternating current stimulation (ACS) can be used to im-
prove brain excitability or resynchronize neuronal oscilla-
tions. ACS uses weak current pulses delivered through
electrodes placed on the forehead for someminutes daily, for
a period of 10 days on average. Electroencephalography and
functional magnetic resonance demonstrated local activa-
tion of the visual cortex, reorganization of the neural
pathways, and enhanced blood flow in the stimulated area.
ACS showed proregenerative effects in controlled trials in
patients with glaucoma and optic neuropathy.
,e process of physiological plasticity can be enhanced
by neurorehabilitation cycles, which can be further sup-
ported by the utilization of neurotrophic factors.
Other technologies indicated in this field are epiretinal
electrode implants, which stimulate RGCs, subretinal elec-
trodes, transchoroidal implants, devices acting on the optic
nerve, and cortical implants, which target the brain areas
responsible for vision. ,e latter could be the most suitable
therapeutic strategy to target the latest stages of glaucoma,
where no function of the optic nerve is left [81, 82]. However,
although the results are promising, the ultimate goal of
restoring good vision is still almost a mirage, and several
limitations and problems still have to be overcome in order
to give these new technologies a clinical application. Re-
garding epiretinal implants, all the studies described left the
patients far below the limit of legal blindness (20/200) and all
the stimuli were unable to maintain specific retinotopy.
Moreover, this is an invasive approach, highly anatomically
destructive, and without the possibility of recovery in case of
device failure. Subretinal implants, when compared to the
previous ones, are more stable as they are implanted beneath
the retina, they do not require connection to external de-
vices, and their stimulation thresholds are lower. Never-
theless, this technology is still invasive and provides a
minimal or no visual recovery. Transchoroidal implants are
less invasive but require a higher stimulation. ,e possibility
of acting directly on the optic nerve should theoretically
allow stimulating both the central and peripheral visual field
with a lower intensity of the stimuli and lower invasiveness
since the electrodes are localized in a smaller area. Several
kinds of implants have been proposed [83], which permitted
the perception of light and spatial orientation in a small
number of cases. However, it has been shown that with time
the intensity of the stimuli required becomes higher, and this
is probably due to the development of gliosis surrounding
the implant after time. Finally, cortical implants showed
encouraging results in the study of Dobelle [84], but in order
to decrease the intensity of stimulation thresholds, pene-
trative cortical implants should be used, which would lead to
higher invasiveness, risk of infection, and inflammation with
reactive gliosis and neuronal death.
,us, subsequent studies are needed to fully understand
the mechanisms that are implied and to refine these devices.
4. Conclusions
Glaucoma is an increasingly widespread social disease and
many advances have been achieved to improve the diag-
nostic and therapeutic resources available (Table 1). How-
ever, new options need to be further enhanced and
supported by significant experimental data on the biological
responses of intraocular and brain tissues, in particular
trabecular cells, RGCs, retinal fibers, and optical pathways.
,e union between clinic, biology, and biotechnology and
their synchronous enforcement appears to be the winning
strategy to defeat the “silent thief of sight”: the challenge is
still open.
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